4ABU LILA A S, ISHIDA T, KIWADA H, et al. Recent advances in tumor vasculature targeting using liposomal drug delivery systems [ J ]. Expert Opin Drug Deliv, 2009, 6(12): 1297-1309.
5CHESON B D, PFISTNER B, JUWEID M E, et al. Revised response criteria for malignant lymphoma [ J ]. J Clin Oncol, 2007, 25(5): 579-586.
6ALBERTS D S, GARCIA D J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer [ J ] . Drugs, 1997, 54(Suppl 4): 30-35.
7THEODOULOU M, HUDIS C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin [ J ] . Cancer, 2004, 100(10): 1052-1063.
8ORLOVSKI R Z, NAGLER A, SONNEVELD P, et al. Randomized phase Ⅲ study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression [ J ] . J Clin Oncol, 2007, 25(25): 3892-3901.
9PULINI S, RUPOLI S, GOTERI G, et al. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas [ J ]. Haematologica, 2007, 2(05): 686-689.
10LORUSSO D, Di STEFANO A, CARONE V, et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia('hand-foot'syndrome) [ J ] . Ann Oncol, 2007, 18(7): 1159-1164.
